NCT05583526
If you're considering treatment options, we invite you to learn more about the Tranquillo clinical trial
This study will help us learn if an oral investigational or study medicine is safe and if it could potentially treat vitiligo.
Who may participate
Each clinical study has its own guidelines for who can participate, called eligibility criteria. However, only the research study staff can determine if you qualify to enroll in the study.
Get started — See if you may qualify
A first step as you consider this study is to answer a five-minute questionnaire about your health and medical history. If your answers show the study might be a good fit for you, you may choose to be referred to a study clinic that you select.
You will then be asked to provide your contact information for a study representative to contact you and discuss the next steps. If you’re interested, they will do a more detailed review of your medical history to see if you are able to participate. Only the study staff can determine if you meet the study’s eligibility criteria and are able to enroll in the study.
Your answers to these initial questions will only be linked to you if your responses indicate that you may be eligible to participate in this study and you choose to share your contact information with the study team. Pfizer study team members and our partners will have access to reports containing aggregated data that will not be directly linked back to you.
What to expect
An important contribution
An important contribution
Vitiligo is personal. When it comes to your skin, the best decision is your own. Wherever you are on your journey with vitiligo, we want to meet you where you are. By taking part in the Tranquillo clinical trial (or study), you could help advance research for people who have vitiligo. So, thank you for taking the time to learn more.
An important contribution

Frequently asked questions
What is vitiligo?
For people with vitiligo, the relationship they have with their skin is a personal one. Because everyone’s journey with vitiligo is different, the best decision when it comes to their condition is their own.
As you may know, nonsegmental vitiligo is defined as an autoimmune condition. This means the immune system attacks healthy cells; in this case, pigment (or color)-producing cells called melanocytes.
What is the investigational (or study) medicine and how does it work?
The investigational medicine, ritlecitinib, is [a janus kinase 3 (JAK3) inhibitor. It’s thought to work by blocking the signals and cells in the body that are believed to cause vitiligo.
Will I receive the study drug?
Your study group will be chosen randomly (like flipping a coin) rather than by choice. This is called randomization, and it’s one way to help avoid bias in a research study. You have a 33% (1 in 3) chance of receiving the placebo. Since this study is double-blinded, neither you, your study doctor, nor the study team will know if you receive the study medicine or the placebo.
How is the study drug taken?
The study medicine is a once-daily oral capsule that you’ll take for approximately one year. If possible, take it around the same time every day, with or without food. On study visit days, we ask that you take your dose at the site instead of at home.